-
PROVIDERS
READ NOW
Minimal residual disease (MRD) testing: A practical guide for clinicians
-
LIFE SCIENCES
READ NOW
Q&A: Harnessing generative AI to refine clinical research & drug development
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
09/15/2025
Minimal residual disease (MRD) testing: A practical guide for clinicians
This white paper offers a practical overview of MRD testing, covering ctDNA detection, tumor-informed vs. tumor-naive approaches, and its role in cancer surveillance and recurrence risk management.
-
06/25/2024Revolutionizing Cardiac Care: AI-driven detection and treatment of critical heart valve disease at Boulder Community Health
Discover how Tempus Next's AI-powered care pathway platform transformed patient outcomes by helping ensure timely, guideline-directed treatment for critical heart valve disease at Boulder Community Health
Read more -
04/15/2024Identifying patients with Valvular Heart Disease: A partnership between St.Francis and Tempus
Learn how the deployment of Tempus Next, an AI-enabled clinical care pathway solution at St. Francis enabled guideline directed care for patients with structural heart disease.
Read more -
04/15/2024Closing the biomarker testing gap for early stage NSCLC patients with Tempus Next
Learn how Tempus Next was deployed at TriHealth Cancer and Blood Institute in Cincinnati, Ohio to surface and close gaps in biomarker testing for NSCLC patients.
Read more